Functional differences between two classes of oncogenic mutation in the PIK3CA gene

被引:45
|
作者
Chaussade, Claire [1 ,3 ]
Cho, Kitty [1 ]
Mawson, Claire [2 ]
Rewcastle, Gordon W. [2 ,3 ]
Shepherd, Peter R. [1 ,3 ]
机构
[1] Univ Auckland, Dept Mol Med, Auckland, New Zealand
[2] Univ Auckland, Auckland Canc Soc Res Ctr, Auckland, New Zealand
[3] Univ Auckland, Maurice Wilkins Ctr Mol Biodiscovery, Auckland, New Zealand
关键词
PI; 3-kinase; Cancer; PI-103; PIK-75; Ras; p110; alpha; PHOSPHOINOSITIDE; 3-KINASE; KINASE-ACTIVITY; BIOLOGICAL EVALUATION; HUMAN CANCER; P110-ALPHA; RAS; ISOFORMS; ACTIVATION; MECHANISM; SUBUNIT;
D O I
10.1016/j.bbrc.2009.02.081
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
PIK3CA codes for the p110 alpha isoform of class-IA PI 3-kinase and oncogenic mutations in the helical domain and kinase domain are common in several cancers. We Studied the biochemical properties of a common helical domain mutant (E545K) and a common kinase domain mutant (H1047R). Both retain the ability to autophosphorylate Ser608 of p85 alpha and are also inhibited by a range of PI 3-kinase inhibitors (Wortmanin, LY294002, PI-103 and PIK-75) to a similar extent as WT p110 alpha. Both mutants display an increased V-max but while a PDGF derived diphosphotyrosylpeptide caused all increase in V-max for WT p85 alpha/p110 alpha it did not for the E545K variant and actually decreased V-max for the H1047R variant. Further, the E545K mutant was activated by H-Ras whereas the H1047R mutant was not. Together these results suggest helical domain mutants are in a state mimicking activation by growth factors whereas kinase domain mutants mimic the state activated by H-Ras. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:577 / 581
页数:5
相关论文
共 50 条
  • [31] PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
    Loi, Sherene
    Michiels, Stefan
    Baselga, Jose
    Bartlett, John M. S.
    Singhal, Sandeep K.
    Sabine, Vicky S.
    Sims, Andrew H.
    Sahmoud, Tarek
    Dixon, J. Michael
    Piccart, Martine J.
    Sotiriou, Christos
    PLOS ONE, 2013, 8 (01):
  • [32] Activation of diverse signalling pathways by oncogenic PIK3CA mutations
    Xinyan Wu
    Santosh Renuse
    Nandini A. Sahasrabuddhe
    Muhammad Saddiq Zahari
    Raghothama Chaerkady
    Min-Sik Kim
    Raja S. Nirujogi
    Morassa Mohseni
    Praveen Kumar
    Rajesh Raju
    Jun Zhong
    Jian Yang
    Johnathan Neiswinger
    Jun-Seop Jeong
    Robert Newman
    Maureen A. Powers
    Babu Lal Somani
    Edward Gabrielson
    Saraswati Sukumar
    Vered Stearns
    Jiang Qian
    Heng Zhu
    Bert Vogelstein
    Ben Ho Park
    Akhilesh Pandey
    Nature Communications, 5
  • [33] Cancer-specific mutations in PIK3CA are oncogenic in vivo
    Bader, AG
    Kang, SY
    Vogt, PK
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (05) : 1475 - 1479
  • [34] Oncogenic PIK3CA mutations in lobular breast cancer progression
    Christgen, Matthias
    Noskowicz, Monika
    Schipper, Elisa
    Christgen, Henriette
    Heil, Charlotte
    Krech, Till
    Laenger, Florian
    Kreipe, Hans
    Lehmann, Ulrich
    GENES CHROMOSOMES & CANCER, 2013, 52 (01): : 69 - 80
  • [35] Activation of diverse signalling pathways by oncogenic PIK3CA mutations
    Wu, Xinyan
    Renuse, Santosh
    Sahasrabuddhe, Nandini A.
    Zahari, Muhammad Saddiq
    Chaerkady, Raghothama
    Kim, Min-Sik
    Nirujogi, Raja S.
    Mohseni, Morassa
    Kumar, Praveen
    Raju, Rajesh
    Zhong, Jun
    Yang, Jian
    Neiswinger, Johnathan
    Jeong, Jun-Seop
    Newman, Robert
    Powers, Maureen A.
    Somani, Babu Lal
    Gabrielson, Edward
    Sukumar, Saraswati
    Stearns, Vered
    Qian, Jiang
    Zhu, Heng
    Vogelstein, Bert
    Park, Ben Ho
    Pandey, Akhilesh
    NATURE COMMUNICATIONS, 2014, 5
  • [36] Oncogenic PIK3CA corrupts growth factor signaling specificity
    Madsen, Ralitsa R.
    Le Marois, Alix
    Mruk, Oliwia N.
    Voliotis, Margaritis
    Yin, Shaozhen
    Sufi, Jahangir
    Qin, Xiao
    Zhao, Salome J.
    Gorczynska, Julia
    Morelli, Daniele
    Davidson, Lindsay
    Sahai, Erik
    Korolchuk, Viktor, I
    Tape, Christopher J.
    Vanhaesebroeck, Bart
    MOLECULAR SYSTEMS BIOLOGY, 2025, 21 (02) : 126 - 157
  • [37] Knockin of mutant PIK3CA activates multiple oncogenic pathways
    Gustin, John P.
    Karakas, Bedri
    Weiss, Michele B.
    Abukhdeir, Abde M.
    Lauring, Josh
    Garay, Joseph P.
    Cosgrove, David
    Tamaki, Akina
    Konishi, Hiroyuki
    Konishi, Yuko
    Mohseni, Morassa
    Wang, Grace
    Rosen, D. Marc
    Denmeade, Samuel R.
    Higgins, Michaela J.
    Vitolo, Michele I.
    Bachman, Kurtis E.
    Park, Ben Ho
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (08) : 2835 - 2840
  • [38] Proximity labeling with molecular signal sensing of oncogenic PIK3CA
    Li, Rong
    Lee, Donghee
    Abdullah, Md
    Kim, Jong Hyuk
    CANCER RESEARCH, 2024, 84 (06)
  • [39] Oncogenic PIK3CA fortifies immune determinants in vascular cancers
    Lee, Donghee
    Kozurek, Emma
    Abdullah, Md
    Li, Rong
    Dickerson, Erin B.
    Kim, Jong Hyuk
    CANCER RESEARCH, 2024, 84 (06)
  • [40] PIK3CA oncogenic mutations in neoadjuvant treatments for breast cancer
    Corso, Giovanni
    Veronesi, Paolo
    Intra, Mattia
    Sacchini, Virgilio
    Galimberti, Viviana
    BIOMARKERS IN MEDICINE, 2017, 11 (07) : 519 - 521